Johns Hopkins doles out pneumonia prevention grants

The International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health doled out 12 grants as part of its 2012 Small Grants for World Pneumonia Day Advocacy Program.

The program supports events and activities that promote pneumonia prevention and control in countries where childhood pneumonia has the greatest impact. Since 2009, applicants to the program have tripled, Johns Hopkins officials say. In 2011, the school awarded 24 small grants of $10,000 or less.

Pneumonia is an infection of the lungs that can cause mild to severe illness. In 2011, nearly 1.3 million children under the age of 5 died from pneumonia; 90% lived in developing countries.

This year's grant winners are as follows:

  • Burkina Faso: Association of Community Health and Development

  • Cameroon: Front for Inter-School Awareness on STD/AIDS

  • Cote d'Ivoire: Stop Tuberculosis Bouake

  • Ghana: Association of People for Practical Life Education in collaboration with Reliance Network

  • Haiti: Haitian Pediatric Society

  • India: Global Health Strategies, India

  • Nigeria: Breath of Life; Vaccine Network; University of Ibadan; Pediatric Association of Nigeria

  • Philippines: Philippines Foundation for Vaccination

  • Zambia: Social Workers Association of Zambia

- get more from News-Medical

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.